Repare Therapeutics Q2 net loss narrows to $16.7 mln

Repare Therapeutics

08/08/2025 12:17

Overview

Repare Therapeutics Q2 net loss narrows to $16.7 mln from $34.8 mln last year

Co entered worldwide licensing agreement with Debiopharm for lunresertib

Exploring strategic alternatives to maximize shareholder value

Outlook

Company expects Q4 2025 data from LIONS and POLAR trials

Repare exploring strategic alternatives to maximize shareholder value

Company anticipates milestone payments from Debiopharm licensing deal

Repare expects initial trial data in Q4 2025

Result Drivers

OUT-LICENSING - Out-licensed early-stage discovery platforms to DCx Biotherapeutics, resulting in a $5.7 mln gain

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.39
Q2 Net Income
-$16.74 mln
Q2 Income From Operations
-$17.78 mln
Q2 Operating Expenses
$23.70 mln
Q2 Pretax Profit
-$16.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Repare Therapeutics Inc is $5.00, about 69.6% above its August 7 closing price of $1.52

Press Release: ID:nBw2yZ68Qa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)